Generic Aggrenox Launched
July 1, 2015 - Teva Pharmaceuticals launched the first U.S. Food and Drug Administration (FDA) approved AB-rated generic to Aggrenox (aspirin/extended release dipyridamole capsules). Originally manufactured by Boehringer Ingelheim and approved by the FDA on August 14, 2009, aspirin/dipyridamole is used to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis. Similar to Aggrenox, Teva’s generic is available in 25mg/200mg extended-release capsules, and is recommended to be taken as one capsule twice daily (morning and evening) with or without food.
Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.
- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval. Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability. All trademarks are the property of their respective owners.
*This is provided for information only. The reference to any medication above does not mean the medication is covered by your plan.